Information Provided By: 
Fly News Breaks for February 28, 2019
PGTI
Feb 28, 2019 | 08:10 EDT
As previously reported, Wells Fargo analyst Truman Patterson downgraded PGT Innovations to Market Perform from Outperform as his EBITDA estimate drops 11% to $148M, primarily due to a change in end-market conditions, and a material drop in margin assumptions. The analyst believes Core Florida R&R revenue growth will likely be negative in Q1, driving negative margin mix shift, and setting the stage for a more challenging 2019. Patterson also lowered his price target on the shares to $17 from $27.
News For PGTI From the Last 2 Days
PGTI
Apr 23, 2024 | 08:31 EDT
New option listings for April 23rd include Express Inc (EXPRQ). Option delistings effective April 23rd include PGT Innovations Inc (PGTI), NGM Biopharmaceuticals Inc (NGM), Karuna Therapeutics Inc (KRTX), KINNATE BIOPHARMA INC (KNTE), Daseke Inc (DSKE), Tritium Dcfc Ltd (DCFC), Xtrackers MSCI All China Equity ETF (CN), CymaBay Therapeutics Inc (CBAY), Alteryx Inc (AYX), XTRACKERS MSCI CHINA A INCLUSION EQUITY ETF (ASHX), Recro Pharma, Inc. (SCTL), Splunk Inc (SPLK), and Textainer Group Holdings Limited (TGH).
